Ordaos

Ordaos designs therapeutic proteins from scratch rather than searching existing molecules and runs internal therapeutic programs and pharma and biotech partnerships built on generative AI–designed miniPRO proteins. Its Design Engine uses multitask meta-learning to create and evaluate de novo protein sequences, structures, and properties in silico.

The Ordaos Design Engine uses generative AI, multitask meta-learning, and reinforcement learning to create and evaluate de novo proteins in silico, while miniPRO proteins are designed to provide antibody-like performance while being more configurable, stable, and easier to manufacture. miniPRO proteins are about twenty times smaller than traditional monoclonal antibodies, helping them penetrate disease microenvironments, and Ordaos serves drug hunters creating novel therapies.